4-Methylpiperidine → 4-(2,6-Diethyl-1,1-dioxo-1lambda6-[1,2,6]thiadiazinan-4-yl)-2-(4-methyl-piperidin-1-yl)-phenylamine

HRID 448011노트

반응식

HRID 448011 반응식
C(OC(=O)[NH:7][C:8]1[CH:13]=[CH:12][C:11]([CH:14]2[CH2:19][N:18]([CH2:20][CH3:21])[S:17](=[O:23])(=[O:22])[N:16]([CH2:24][CH3:25])[CH2:15]2)=[CH:10][C:9]=1Br)(C)(C)C.[CH3:28][CH:29]1[CH2:34][CH2:33][NH:32][CH2:31][CH2:30]1>>[CH2:24]([N:16]1[CH2:15][CH:14]([C:11]2[CH:12]=[CH:13][C:8]([NH2:7])=[C:9]([N:32]3[CH2:33][CH2:34][CH:29]([CH3:28])[CH2:30][CH2:31]3)[CH:10]=2)[CH2:19][N:18]([CH2:20][CH3:21])[S:17]1(=[O:23])=[O:22])[CH3:25]

참가 물질

3

실험 절차

The title compound is prepared from [2-bromo-4-(2,6-diethyl-1,1-dioxo-1λ6-[1,2,6]thiadiazinan-4-yl)-phenyl]-carbamic acid tert-butyl ester (as prepared in the previous step) and 4-methylpiperidine following the literature procedure of Buchwald (Org. Lett., 4, 2885-8 (2002)). The residue obtained is purified by silica gel chromatography with an appropriate solvent mixture. After isolation, removal of the BOC protecting group from the resulting intermediate is carried out by stirring at RT in TFA-DCM (1:2), monitoring by TLC for completion, and then concentration in vacuo.

후처리

  1. customThe residue obtained
  2. customis purified by silica gel chromatography with an appropriate solvent mixture
  3. customAfter isolation, removal of the BOC protecting group from the resulting intermediate
  4. concentrationconcentration in vacuo

출처 및 근거

ORD 기록
ord-80000aac0e514bd3992ac11065ca86b7
출처 데이터셋
uspto-grants-2013_07
특허 번호
US08481564B2

반응 노트

불러오는 중…